Completed PHASE4 INTERVENTIONAL 3-arm
NCT06823180
Hydromorphone Hydrochloride Epidural Preemptive Analgesia for Postoperative Pain After Cesarean Section (HHEPA)
Clinical Effect of Hydromorphone Hydrochloride Epidural Preemptive Analgesia on Postoperative Pain After Cesarean Section
Sponsor: Liquan Liang
Conditions
Post-surgical Pain
Interventions
0.9% sodium chloride Hydromorphone hydrochloride high dose Hydromorphone hydrochloride low dose
Updated 2 times since 2025 Last updated: Aug 28, 2025 Started: Mar 3, 2025 Primary completion: Aug 28, 2025 Completion: Aug 28, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE4 clinical study on Post-surgical Pain, this trial is completed. The trial is conducted by Liquan Liang and has accumulated 2 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
2 versions recorded-
Oct 2025 — Present [monthly]
Completed PHASE4
Status: Not Yet Recruiting → Completed
-
Mar 2025 — Oct 2025 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Liquan Liang
Data source: Jiangxi Provincial People's Hopital
For direct contact, visit the study record on ClinicalTrials.gov .